Generics News
Generics
US president Donald Trump has set a countdown for tariffs on imported generic medicines, ending an exemption that had shielded the copycat drugs supplying the bulk of US prescriptions. Announcing the plan on his Truth Social platform, he framed the levies as a penalty for companies that decline to shift production onto American soil. 23 July 2026
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Generics
The US Supreme Court has handed a unanimous win to British drugmaker Hikma in a closely watched generics patent case brought by Irish biopharma Amarin. 5 June 2026
Most Read
Companies, Mergers & Acquisitions
Company Spotlight
Recent news
Generics
A formulation manufacturing unit of Indian drugmaker Aurobindo Pharma’s subsidiary Eugia Pharma Specialities near Hyderabad has received a warning letter from the US Food and Drug Administration (FDA). The unit had earlier received four observations and an Official Action Indicated (OAI) status from the US regulator, according to a report by The Hindu. 17 August 2026
Generics
Malta-headquartered Adalvo and Hungary’s Gedeon Richter have announced an expanded global partnership to co-develop and supply therapies based on tirzepatide, the active ingredient of Eli Lilly’s Mounjaro and Zepbound. 10 August 2026
Generics
Mumbai, India-based RPG Life Sciences is restructuring its active pharmaceutical ingredient (API) operations into a dedicated subsidiary, RPG Active Pharma, with the backing of healthcare-focused private equity investor InvAscent. 10 August 2026
Generics
The Russian government has opposed the recently made proposal to grant the domestic patent service Rospatent the right to pre-trial block the distribution of drugs whose release infringes patents on original drugs, reports The Phara Letter's local correspondent. 6 August 2026
Generics
Swiss affordable medicines company Sandoz today announced several steps to further resolve the US Generic Drug Antitrust Pricing Litigation. 3 August 2026
Refine search
In Brief
Generics
10 February 2026 Japan’s Astellas Pharma announced that it has reached an agreement with Lupin Limited and Lupin Pharmaceuticals to settle pending US patent litigation regarding Astellas’ Myrbetriq (mirabegron), a treatment for overactive bladder (OAB).
Generics
18 November 2025 India’s Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for diroximel fumarate delayed-release capsules, 231mg (Biogen’s Vumerity delayed-release capsules, 231mg).
Insights
Generics
The Russian Patent and Trademark Office refused to overturn the patent for the anticoagulant apixaban, which is owned by US pharma major Bristol Myers Squibb on the basis of the claim filed by the Israeli pharmaceutical company Teva Pharmaceutical Industries, reports The Pharma Letter’s local correspondent. 25 June 2026
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Generics
Russia will have its own generic of one of the world’s most expensive drug against cystic fibrosis, as the Russian pharmaceutical company Amedart announced its plans launch a domestic analogue of Trikafta (elexacaftor/tezacaftor/ivacaftor), a drug from the American company Vertex Pharmaceuticals for the treatment of cystic fibrosis, reports The Pharma Letter’s local correspondent. 5 June 2026
Generics
Indian pharmaceutical companies have pledged an unprecedented $19.1 billion in investments across the USA, marking a watershed moment in bilateral healthcare collaboration. 11 May 2026
Generics
The share of generics in the Russian pharmaceutical market will grow in the coming years, both in the pharmacy segment and in government procurement, according to latest forecasts made by experts of the Russian analyst agency in the field of pharmaceutics DSM Group. 11 May 2026
Generics
Russia is experiencing a boom of sales of obesity drugs, which is mainly due to the recent launch of some domestically developed drugs in this market segment, reports The Pharma Letter’s local correspondent. 8 May 2026
Generics
Axelpharm, the Russian manufacturer of anticancer generics, may suspend operations due to fines from the local antitrust regulator the Federal Antimonopoly Service (FAS), which were imposed for the company’s participation in patent disputes. 21 April 2026
Boardroom
The UK subsidiary of German generics, biosimilars and consumer healthcare major STADA Arzneimittel is investing a seven-figure sum in an expanded, state-of-the-art commercial office in Green Park, Reading, as it advances its ambition of establishing the business as a British consumer healthcare and pharmaceutical powerhouse. 27 May 2026
Hikma Pharmaceuticals today reported its audited results for the year ended December 31, 2025. The company’s shares were down almost 15% at 1,406 pence by early afternoon. 26 February 2026
The board of directors of the USA’s Association for Accessible Medicines (AAM) has elected Bob Hoffman as chairman. Mr Hoffman, chief commercial officer of US generics for Lupin Pharmaceuticals, most recently served as vice chairman of the AAM board for the past two terms. 30 January 2026
Effective January1, 2026, STADA Arzneimitel’s global head of communications, Frank Staud, is additionally assuming global responsibility for STADA’s global government affairs, the German generics and consumer healthcare major announced today. 16 January 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze